Format

Send to

Choose Destination
Eur J Oncol Nurs. 2014 Dec;18(6):645-8. doi: 10.1016/j.ejon.2014.05.006. Epub 2014 Jun 20.

Validation of the G8 screening tool in older patients with aggressive haematological malignancies.

Author information

1
Department of Geriatrics, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium. Electronic address: Anja.velghe@uzgent.be.
2
Department of Geriatrics, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium. Electronic address: Mirko.petrovic@ugent.be.
3
Department of Geriatrics, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium. Electronic address: Stefanie.debuyser@ugent.be.
4
Department of Geriatrics, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium. Electronic address: Rein.demuynck@uzgent.be.
5
Department of Haematology, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium. Electronic address: Lucien.noens@ugent.be.

Abstract

BACKGROUND:

Incidence rates of haematological malignancies increase with age. In these older cancer patients, important information may be missed without a Comprehensive Geriatric Assessment (CGA). A validated screening instrument is needed to identify those patients for whom a CGA would be beneficial. The G8 has recently been validated as a screening tool for older cancer patients in need of a CGA.

OBJECTIVES:

To test the performance of the G8 screening tool in older patients with aggressive haematological malignancies to identify those who would benefit from a CGA.

METHODS:

Cross-sectional study of patients ≥70 years with a recently diagnosed haematological malignancy. G8, CGA (including six questionnaires) and Cumulative Illness Rating Scale for Geriatrics (CIRS-G) were completed in each patient. The CGA was considered abnormal when at least one questionnaire showed an impaired score.

RESULTS:

Fifty patients with median age of 76 years were included; 88% (N = 44) had an abnormal CGA. ROC curve analyses revealed a G8 score ≤14 obtained a sensitivity of 89% (95% CI 75-96) and a specificity of 100% (95% CI 54-100), suggesting an optimal cut-off point. AUC ± SE was 0.949 ± 0.030. Inclusion of comorbidity in the CGA did not change the performance of the G8 (0.943 ± 0.034; P = 0.895).

CONCLUSION:

The G8 can be used as a valid screening tool in older patients with aggressive haematological malignancies to identify those patients who would benefit from a CGA. Comorbidity should be assessed routinely and independently of the G8.

KEYWORDS:

Aggressive haematological malignancy; CIRS-G; Comprehensive geriatric assessment; G8 screening tool; Older cancer patient; Validation

PMID:
24954768
DOI:
10.1016/j.ejon.2014.05.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center